Reason for request
Re-assessment of methylphenidate-based proprietary products in attention-deficit hyperactivity disorder in response to a request from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of CONCERTA LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years and over when psychological, educational and social management alone prove insufficient. |
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
ChAWqYJy0WQ7M9tJ
